# Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

> **NCT04676529** · PHASE1,PHASE2 · COMPLETED · sponsor: **Syntara** · enrollment: 43 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** PXS-5505

## Key facts

- **NCT ID:** NCT04676529
- **Lead sponsor:** Syntara
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-18
- **Primary completion:** 2025-07-09
- **Final completion:** 2025-07-09
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676529, "Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04676529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*